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IMPORTANCE Obesity is a risk factor for deep vein thrombosis of the leg and pulmonary
embolism. To date, however, whether obesity is associated with adult cerebral venous
thrombosis (CVT) has not been assessed.
OBJECTIVE To assess whether obesity is a risk factor for CVT.
DESIGN, SETTING, AND PARTICIPANTS A case-control studywas performed in consecutive
adult patients with CVT admitted from July 1, 2006 (Amsterdam), and October 1, 2009
(Berne), through December 31, 2014, to the Academic Medical Center in Amsterdam, the
Netherlands, or Inselspital University Hospital in Berne, Switzerland. The control group was
composed of individuals from the control population of theMultiple Environmental and
Genetic Assessment of Risk Factors for Venous Thrombosis study, which was a large Dutch
case-control study performed fromMarch 1, 1999, to September 31, 2004, and in which risk
factors for deep vein thrombosis and pulmonary embolismwere assessed. Data analysis was
performed from January 2 to July 12, 2015.
MAIN OUTCOMES ANDMEASURES Obesity was determined by bodymass index (BMI). A BMI
of 30 or greater was considered to indicate obesity, and a BMI of 25 to 29.99 was considered
to indicate overweight. A multiple imputation procedure was used for missing data. We
adjusted for sex, age, history of cancer, ethnicity, smoking status, and oral contraceptive use.
Individuals with normal weight (BMI <25) were the reference category.
RESULTS The study included 186 cases and 6134 controls. Cases were younger (median age,
40 vs 48 years), more often female (133 [71.5%] vs 3220 [52.5%]), more often used oral
contraceptives (97 [72.9%] vs 758 [23.5%] of women), andmore frequently had a history of
cancer (17 [9.1%] vs 235 [3.8%]) compared with controls. Obesity (BMI30) was associated
with an increased risk of CVT (adjusted odds ratio [OR], 2.63; 95% CI, 1.53-4.54).
Stratification by sex revealed a strong association between CVT and obesity in women
(adjusted OR, 3.50; 95% CI, 2.00-6.14) but not in men (adjusted OR, 1.16; 95% CI, 0.25-5.30).
Further stratification revealed that, in womenwho used oral contraceptives, overweight and
obesity were associated with an increased risk of CVT in a dose-dependent manner (BMI
25.0-29.9: adjusted OR, 11.87; 95% CI, 5.94-23.74; BMI30: adjusted OR, 29.26; 95% CI,
13.47-63.60). No association was found in womenwho did not use oral contraceptives.
CONCLUSIONS AND RELEVANCE Obesity is a strong risk factor for CVT in womenwho use oral
contraceptives.
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V arious studies1-6 have identified obesity as a risk fac-tor for deep vein thrombosis of the leg andpulmonaryembolism, collectively called venous thromboembo-
lism (VTE). A bodymass index (BMI) (calculated as weight in
kilograms divided by height inmeters squared) of 30 ormore
increases the risk ofVTEapproximately 2-fold comparedwith
a normal BMI (<25), and this risk increases more with higher
BMIs. Individualswith aBMIgreater than40have anapproxi-
mately 3 times higher risk.
Cerebralvenous thrombosis (CVT) isa rare thromboticcon-
dition thatmainly affects youngadults andchildren.7Risk fac-
tors for CVT partly overlap with those for VTE and include
thrombophilia, cancer, andoral contraceptiveuse.8,9Other risk
factors, such as local infections and head trauma, are specific
for CVT.10 Some diseases, such as acute lymphoblastic leuke-
mia, are associated with CVT and VTE, but the association is
stronger for CVT.11
Toourknowledge,whetherobesity isassociatedwithadult
CVT has not been assessed. One study12 found that obesity is
morecommon inchildrenwithCVT (55%)comparedwithcon-
trols (32%), but the sample size was small (22 cases). In addi-
tion, this study12 used historical controls and did not adjust
for confoundingvariables.Moreover, because the clinical pre-
sentation and risk factors of CVTaredifferent for children and
adults,13 this result cannot be generalized to adult patients. In
the current study, we examined whether obesity is a risk fac-
tor for adult CVT.
Methods
Study Design and Patient Selection
We performed an unmatched case-control study. The con-
trols were recruited from March 1, 1999, through September
31, 2004, and the caseswere recruited fromJuly 1, 2006 (Am-
sterdam), andOctober 1, 2009 (Berne), throughDecember 31,
2014. Data analysis was performed from January 2 to July 12,
2015.
CaseswerepatientswithCVT included in2prospectiveco-
horts from the Academic Medical Center in Amsterdam, the
Netherlands, and InselspitalUniversityHospital inBerne,Swit-
zerland. In these hospitals, data on consecutive adult pa-
tientswith CVThave been recorded since July 2006 (Amster-
dam) and October 2009 (Berne). We included patients who
wereadmitteduntilDecember2014.Thediagnosis ofCVTwas
confirmed with computed tomography venography, mag-
netic resonance imaging and magnetic resonance venogra-
phy, angiography, or autopsy in all patients in accordancewith
international guidelines.14
Controlswerehealthy individualswhoparticipated in the
DutchMultipleEnvironmental andGeneticAssessmentofRisk
Factors for Venous Thrombosis (MEGA) study.15 The MEGA
study isacase-control studyperformed in theNetherlands that
included4956 consecutive patients aged 18 to 70yearswith a
first deep vein thrombosis of the leg or pulmonary embolism
from March 1, 1999, through September 31, 2004. Details of
this study have been reported.15 Partners of patients and in-
dividuals identifiedby randomdigit dialingwere asked topar-
ticipate as controls. In total, 6297 controls (3297 partners and
3000 identifiedby randomdigit dialing)were included.These
participantswerebetween the ages of 18 and70years andhad
no history of venous thrombosis.We excludedwomen (cases
and controls) whowere pregnant or had given birth less than
12 weeks earlier.
The Medical Ethics Committee Academic Medical Cen-
ter, CommitteeMedical EthicsLeidenUniversityMedicalCen-
tre, andCantonalEthicsCommissionBernapproved the study.
Written informed consent was obtained from all participants
included in theMEGAstudy and theBerne cohort. For the pa-
tientswithCVT included in theAmsterdamcohort,written in-
formedconsentwasnot requiredunderDutch lawbecauseonly
observational data were collected.
Data Collection and Definition of Obesity
Baseline characteristics, risk factors for thrombosis, imaging
findings, and clinical outcome were recorded using a stan-
dardized case report form for cases. Each control completed
a detailed questionnaire on acquired risk factors for throm-
bosis,which includedself-reportedcurrentheight andweight.
In accordance with the definitions of the World Health Orga-
nization, BMIwas categorized as follows: normalweight, BMI
less than 25; overweight, BMI of 25 to 29.99; and obesity, BMI
of 30 or greater.
Statistical Analysis
Amultiple imputationprocedurewasused formissingdataon
height, weight, oral contraceptive use, smoking status, his-
tory of cancer, and ethnicity.16 In total, 5 data sets were im-
puted, and resultswere pooled according toRubin’s rules.We
applied multivariate logistic regression analysis to study the
association between obesity and CVT. Individualswith a nor-
malBMI (<25)were the reference category. In a separate analy-
sis,we includedBMIasacontinuousvariable in themodel.Un-
adjusted and adjusted odds ratios (ORs) with 95% CIs were
calculated. We adjusted for the following prespecified vari-
ables: sex, age (asacontinuousvariable),historyof cancer, eth-
nicity, smoking status, and oral contraceptive use. On the ba-
sis of a previous report,4 we performed predefined subgroup
analyses inwhichwestudied the influenceof sexandoral con-
traceptive use on the association between obesity and CVT.
P < .05 was considered statistically significant. All data were
analyzedwith SPSS statistical software, version20 (SPSS Inc).
Key Points
Question: Is obesity a risk factor for cerebral venous thrombosis?
Findings: In this case-control study that included 186 cases and
6134 controls, obesity was associated with a statistically significant
3-fold increased risk of cerebral venous thrombosis. Stratification
by sex revealed that in womenwho used oral contraceptives, the
risk was increased 30-fold. In contrast, we found no association in
men or womenwho did not use oral contraceptives.
Meaning:Obesity is a strong risk factor for cerebral venous
thrombosis in womenwho use oral contraceptives.
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Results
There were 192 cases and 6297 controls within the specified
period.Weexcluded6 cases and 163 controls because of preg-
nancyor recent delivery; therefore, the studypopulation con-
sisted of 186 cases and 6134 controls. The numbers of pa-
tients forwhomdataweremissingwereas follows:height, 547
(64cases and483controls);weight, 539 (57 cases and482con-
trols); oral contraceptiveuse, 32 (6 cases and26 controls); his-
tory of cancer, 20 (1 case and 19 controls); smoking status, 487
(57 cases and 430 controls); and ethnicity, 423 (38 cases and
385controls). In total, BMIcouldnotbecalculatedwithout im-
putation in 69 cases because height or weight was not avail-
able. Eleven of these cases (15.9%) had obesity listed in their
medical history.
Caseswereyounger (medianage, 40vs48years),moreof-
ten female (133 [71.5%] vs 3220 [52.5%]),more oftenusedoral
contraceptives (97 [72.9%] vs 758 [23.5%]women), andmore
frequentlyhadahistoryofcancer (17 [9.1%]vs235 [3.8%]) com-
paredwith controls (Table 1). Themost commonclinicalmani-
festations of patients with CVT are provided in Table 2.
Mean BMIwas higher in cases than controls (26.7 vs 25.6,
P = .01). After adjustment for confounding variables, the risk
of CVT was increased in patients with obesity (BMI ≥30; ad-
justedOR,2.63;95%CI, 1.53-4.54)comparedwithpatientswith
a normal BMI (Table 3). Overweight (BMI 25.0-29.99)was not
associated with CVT (adjusted OR, 1.37; 95% CI, 0.80-2.36).
When included as a continuous variable, BMI was also asso-
ciated with an increased risk of CVT (adjusted OR per 1-unit
increase in BMI, 1.09; 95% CI, 1.05-1.13; P < .001).
Stratificationbysex revealednostatistically significant as-
sociation between obesity and the risk of CVT in men (ad-
justed OR, 1.16; 95% CI, 0.25-5.30; Table 4). In women, over-
weight and obesity were associated with CVT (BMI 25-29.9:
adjustedOR, 1.71;95%CI, 1.01-2.91;BMI≥30:adjustedOR,3.50;
95% CI, 2.00-6.14).
We also stratified for oral contraceptive use (Table 5).
Amongwomenwhodidnotuseoral contraceptives,we found
no association between obesity and CVT (BMI ≥30: adjusted
OR, 1.29; 95%CI, 0.46-3.66). In contrast, inwomenwhoused
oral contraceptives, obesity was strongly associated with the
riskofCVT.Comparedwithwomenwith anormalweightwho
didnotuseoral contraceptives, obesewomen takingoral con-
traceptives had a 29-fold increased risk of CVT (adjusted OR,
29.26; 95% CI, 13.47-63.60). The risk of CVT was also in-
creased in overweight women who used oral contraceptives
(BMI 25-29.99: adjusted OR, 11.87; 95% CI, 5.94-23.74).
Discussion
Our study indicates that obesity (BMI ≥30) is associated with
an increased risk of CVT. This association appears to be fully
attributable toa strongly increased risk inwomenwhouseoral
contraceptives. Among thesewomen, obesitywas associated
with an almost 30-fold increased risk of CVT compared with
women of normal weight who did not use oral contracep-
tives. Inmen andwomenwhodonot use oral contraceptives,
we found no association between CVT and obesity.
In VTE, the association with obesity is also stronger in
women thanmen. In a large cohort study,5 a BMI in the high-
est quartile increased the risk of VTE 2.8-fold for women and
1.7-fold formen.Another study3 confirmedsimilar effect sizes.
Only a few studies4,17,18 have examined the interaction be-
tween oral contraceptive use and obesity on the risk of VTE.
Pomp et al4 found an OR of 24 among women with a BMI of
30orgreaterwhousedoral contraceptivescomparedwithnon-
users of oral contraceptiveswhowereofnormalweight. In an-
other study,17 the risk of VTE in oral contraceptive users with
a BMI of 30 or greaterwas increased approximately 10-fold. A
possible interaction between oral contraceptives and obesity
has also been observed in ischemic stroke. In a case-control
study by Kemmeren et al,18 the risk of ischemic stroke in
women who used oral contraceptives was approximately
doubled in those with obesity.
Among oral contraceptive users, the risk of CVT was
higher in those with obesity (BMI ≥30) than in women who
were overweight (BMI 25-29.99). This dose-response effect,
in combination with the magnitude of the effect size and the
evidence that obesity is also associated with VTE,2,4,19 favors
a causal association among obesity, oral contraceptive use,
and CVT.20 One mechanism by which obesity could increase
the risk of thrombosis are changes in coagulation factor lev-
els. Compared with women with a normal weight, obese






Age, median (IQR), y 40 (28-49) 48 (38-57)
Female sex 133/186 (71.5) 3220/6134 (52.5)
Oral contraceptive useb 97/133 (72.9) 758/3220 (23.5)
History of cancer 17/186 (9.1) 235/6134 (3.8)
White ethnicity 167/186 (89.8) 5805/6134 (94.6)
Current smoker 36/186 (19.4) 1980/6134 (32.3)
Abbreviation: IQR, interquartile range.
a Data are presented as number/total number (percentage) of study
participants unless otherwise indicated. The number of events was divided by
the total number (unknown andmissing cases excluded) to calculate the
percentage.
b In women only.
Table 2. Baseline Characteristics of Cerebral Venous Thrombosis Cases
Characteristic
No./Total No. (%)
of Cases (n = 186)a
Headache 163/182 (89.6)
Focal neurologic deficits 115/182 (63.2)
Seizures 79/184 (52.0)
Papilledema 38/148 (25.7)
Hemorrhagic infarcts or intracerebral
hemorrhage
76/182 (41.8)
Cerebral edema or infarction without
hemorrhage
39/182 (21.4)
a The number of cases was divided by the total number (unknown andmissing
cases excluded) to calculate the percentage.
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women have higher plasma concentrations of prothrombotic
factors, such as plasminogen activator inhibitor 1 and
von Willebrand factor.21 Obesity is also associated with
increased activated protein C resistance and higher concen-
trations of factor VIII, which are risk factors for thrombosis.22
Useoforal contraceptivesalso leads to increasedactivatedpro-
teinCresistance,23whichmightexplain thesynergisticeffectof
both risk factors thatwe observed.
It is important todeterminewhether the control groupwe
used is representative of thehealthypopulation. In our study,
the prevalence of a BMI of 30 or greater was 12.6% and 13.8%
amongmale and female controls, respectively. Thesepercent-
ages are similar to the findings of a study24 among healthy
adults from the Netherlands that was performed in the same
period as the MEGA study. The prevalence of a BMI above 25
among men and women is also comparable to the results of
that study.
Of interest, obesity is also a risk factor for idiopathic in-
tracranial hypertension (IIH). Patients with IIH most often
presentwithheadache,papilledema,anddecreasedvisualacu-
ity. Identical symptomsoccur in intracranial hypertensionow-
ing to impaired venous return in patientswith chronic CVT.25
Before the introduction of computed tomography and
magnetic resonance venography, it was not uncommon for
patientswith CVT to bemisdiagnosed as having IIH.26,27 Like
CVT, IIH is far more common in women than inmen, and the
Table 4. Stratification by Sex
BMI
No. (%) of Study Participantsa OR (95% CI)
Cases
(n = 53 Men and
133 Women)
Controls
(n = 2914 Men and
3220 Women) Unadjusted Adjustedb
Men
<25 27 (50.9) 1277 (43.8) 1 [Reference]c 1 [Reference]c
25-29.99 18 (34.0) 1270 (43.6) 0.66 (0.30-1.45) 0.80 (0.35-1.80)
≥30 8 (15.1) 367 (12.6) 1.04 (0.26-4.17) 1.16 (0.25-5.30)
Women
<25 57 (42.9) 1748 (54.3) 1 [Reference]c 1 [Reference]c
25-29.99 42 (31.6) 1028 (31.9) 1.24 (0.75-2.05) 1.71 (1.01-2.91)
≥30 34 (25.6) 444 (13.8) 2.30 (1.39-3.81) 3.50 (2.00-6.14)
Abbreviations: BMI, bodymass index
(calculated as weight in kilograms
divided by height in meters squared);
OR, odds ratio.
a The number of study participants
was divided by the total number
(unknown andmissing cases
excluded) to calculate the
percentage.
b Themultivariate model is adjusted
for age, history of cancer, ethnicity,
and smoking status. In the subgroup
analysis for women, we also
adjusted for oral contraceptive use.
c Patients with a BMI less than 25
were the reference category.
Table 5. Stratification by Oral Contraceptive Use inWomen
BMI
No. (%) of Study Participantsa






<25 17 (13.2) 1190 (37.8) 1 [Reference]c
25-29.99 11 (8.5) 843 (26.8) 0.85 (0.30-2.41)
≥30 7 (5.4) 384 (3.1) 1.29 (0.46-3.66)
OC use
<25 36 (27.9) 486 (15.4) 5.09 (2.58-10.02)
25-29.99 31 (24.0) 186 (5.9) 11.87 (5.94-23.74)
≥30 27 (20.9) 59 (1.9) 29.26 (13.47-63.60)
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); OC, oral contraceptive; OR, odds ratio.
a The number of study participants was divided by the total number (unknown
andmissing cases excluded) to calculate the percentage.
b Themultivariate model is adjusted for age, history of cancer, ethnicity, and
smoking status.
c Patients with a BMI less than 25 without OC use were the reference category.
Table 3. Association BetweenObesity and Cerebral Venous Thrombosis
BMI




(n = 6134) Unadjusted Adjustedb
<25 85 (45.7) 3025 (49.3) 1 [Reference] 1 [Reference]
25-29.99 59 (31.7) 2299 (37.5) 0.93 (0.57-1.50) 1.37 (0.80-2.36)
≥30 42 (22.6) 810 (13.2) 1.85 (1.14-3.00) 2.63 (1.53-4.54)
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); OR, odds ratio.
a The number of study participants was divided by the total number (unknown
andmissing cases excluded) to calculate the percentage.
b Themultivariate model is adjusted for sex, age, history of cancer, ethnicity,
smoking status, and oral contraceptive use.
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associationbetween IIHandobesity is also stronger inwomen
than men.28-30 Given these resemblances, it is intriguing to
speculate on a possible common pathogenesis by which obe-
sity increases the riskofbothconditions inwomen. It hasbeen
hypothesized that IIH is causedbydecreasedoutflow fromthe
cerebralvenoussystem,possiblyowing tostenosisof the trans-
verse sinuses or insufficiency of the valves in the jugular
veins.31,32Studies31,33havesuggestedthatobesityenhances this
mechanism by transmittance of increased intra-abdominal
pressure to the cerebral venous system. On the other hand,
there are also data indicating that the sinus stenosis seen in
IIH is secondary to the increased intracranial pressure and is
reversible after removal of cerebrospinal fluid.34 The effect of
stenting of the cerebral sinuses has been examined in pa-
tients with IIH but only in small and uncontrolled series, and
the data are inconclusive.35,36 Prospective studies37,38 evalu-
ating the efficacy of cerebral venous sinus stenting in IIH are
currently ongoing.
Our study has several limitations. First, we could include
only a relatively small number of patients with CVT, espe-
ciallymenandwomenwithoutoral contraceptiveuse.Wecan-
not exclude that the absent association between obesity and
CVT in these groups is the result of this limited sample size.
Second, we were unable to examine whether genetic throm-
bophilia influences the association between obesity and CVT
because screening for thrombophilia was not performed in
most cases. Thrombophilia should be the focus of a future
study given that there is a synergistic effect betweenoral con-
traceptives and thrombophilia on the risk of CVT9,39 and be-
tween obesity and thrombophilia on the risk of VTE.4 Third,
data on the key variables of height and weight were missing
in a substantial proportion of cases because these measure-
ments were not recorded in all patients. This lack of data on
height andweight couldhaveunderpowered the studyandbi-
ased the results if the reason the data were missing was not
random. To minimize this potential bias, we used a multiple
imputationprocedure.16,40Thefact that 15.9%ofcases inwhich
noBMI could be calculated had obesity listed in theirmedical
history also suggests that obesity was not infrequent among
cases with missing BMI. Fourth, instead of measuring height
andweight,weusedself-reporteddata tocalculateBMI,which
could be less accurate, although a previous study6 found an
excellentcorrelationbetweenself-reportedandmeasuredBMI.
Moreover, becausemeasurementswere self-reported for cases
and controls, any inaccuracywouldbe expected to affect both
groups,whichwoulddecrease the riskof bias. Fifth, therewas
a time difference in recruitment between cases and controls.
The controlswere recruited fromMarch 1, 1999, through Sep-
tember 31, 2004, whereas the cases were recruited from July
1, 2006 (Amsterdam), and October 1, 2009 (Berne), through
December 31, 2014. A change in prevalence of obesity in that
period could theoretically have biased the results. However,
the time difference seems to be too small to explain the re-
sults andwould also not explainwhyweonly observed an as-
sociation inwomenwhousedoral contraceptives. Finally,we
cannot exclude the possibility that residual confounding in-
fluenced the results. Somevariables, suchasobstructive sleep
apnea syndrome,were not available for controls. Obstructive
sleep apnea syndrome is a risk factor for obesity and VTE, al-
though, to our knowledge, an associationwith CVThas never
been reported.41,42
The increasedriskofVTEandCVTassociatedwithoral con-
traceptives in the presence of obesity might make physicians
reluctant toprescribeoralcontraceptivestoobesewomen.How-
ever, although the relative risks are increasedsubstantially, the
absolute risks of CVT are still small.43 Moreover, withholding
oral contraceptivesmay lead toan increase inunintendedpreg-
nancies and thus the number of pregnancy-related thrombo-
sis cases.44 Nevertheless, obese women should be informed
about the increased risk of thrombosis if they use oral contra-
ceptives, especially if other risk factors are present. Alterna-
tive methods of contraception that are not associated with
thrombosis, suchas an intrauterinedevice,mightbeoffered to
these women.
Conclusions
To our knowledge, this is the first case-control study that ex-
amined the association between obesity andCVT. Our results
suggest that obesity is associated with a substantially in-
creasedriskofCVT inwomenwhouseoral contraceptives.This
increased risk should be taken into consideration when pre-
scribing oral contraceptives to obese women.
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